• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Veracyte Inc (NQ: VCYT )

    21.41 -0.26 (-1.20%)
    Streaming Delayed Price Updated: 3:25 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 410,202
    Open 21.59
    Bid (Size) 21.42 (4)
    Ask (Size) 21.44 (1)
    Prev. Close 21.67
    Today's Range 21.18 - 22.11
    52wk Range 18.63 - 30.52
    Shares Outstanding 67,473,870
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets
    Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
    On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
    Via Benzinga

    Performance

    YTD
    -21.86%
    -21.86%
    1 Month
    +3.18%
    +3.18%
    3 Month
    -1.06%
    -1.06%
    6 Month
    -21.86%
    -21.86%
    1 Year
    -14.09%
    -14.09%

    More News

    Read More
    Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
    From Veracyte, Inc.
    Via Business Wire
    A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
    Via Benzinga
    Recap: Veracyte Q4 Earnings
    Via Benzinga
    Earnings Outlook For Veracyte
    Via Benzinga
    Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Participate in Upcoming Investor Conferences
    From Veracyte, Inc.
    Via Business Wire
    VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Veracyte Announces First Quarter 2024 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
    From Veracyte, Inc.
    Via Business Wire
    New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
    From Veracyte, Inc.
    Via Business Wire
    Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
    Via Benzinga
    Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
    Via Benzinga
    Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
    From Veracyte, Inc.
    Via Business Wire
    Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
    Via Benzinga
    7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
    Via InvestorPlace
    Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
    From Veracyte, Inc.
    Via Business Wire
    Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
    From Veracyte, Inc.
    Via Business Wire
    Earnings Scheduled For February 22, 2024
    Via Benzinga
    Veracyte Completes Acquisition of C2i Genomics
    From Veracyte, Inc.
    Via Business Wire
    Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
    From Veracyte, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.